Switching Clonidine IR to Long-Acting Formulation
Conversion Algorithm
- The American College of Cardiology recommends that a patient on clonidine 0.2mg twice daily IR can be directly switched to the transdermal patch formulation at an equivalent dose, specifically the 0.1mg/24hr patch applied weekly 1, 2
- The transdermal clonidine patch delivers drug at a constant rate over 7 days, with available patch strengths including 0.1mg/24hr, 0.2mg/24hr, and 0.3mg/24hr 1, 2
- For a 0.4mg/day oral dose, the American College of Cardiology suggests starting with the 0.1mg/24hr patch, equivalent to approximately 0.7mg/week or 0.1mg/day 1, 2
Critical Safety Considerations
- The American Heart Association, as published in Circulation, warns that never abruptly discontinuing clonidine without tapering or transitioning to the patch can precipitate severe rebound hypertension and hypertensive crisis 1, 2
Advantages of Transdermal Formulation
- The American College of Cardiology notes that the transdermal formulation improves medication adherence with once-weekly application 1, 2